| ²é¿´: 331 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
||
| A question of high priority is whether the approved antiangiogenic regimes are optimally used in terms of dosing, duration, and combination therapy. The role of VEGF (receptor) inhibitors in micrometast atic disease in adjuvant settings (e.g.,upon resection of the primary tumor) will require further research given the paucity of available preclinical data and suitable animal models. |
» ²ÂÄãϲ»¶
304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£©
ÒѾÓÐ18È˻ظ´
Èí¹¤Ñ§Ë¶299Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
»¯¹¤µ÷¼Á303·Ö£¬¹ýËļ¶
ÒѾÓÐ30È˻ظ´
264Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÉúÎ﹤³ÌÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ23È˻ظ´
283Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
22408 һ־Ը˫һÁ÷È˹¤ÖÇÄÜ300·Ö ËÄÁù¼¶£¬Êý¾Ý·ÖÎö¹ú½±
ÒѾÓÐ5È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´

nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-02-01 22:47:50
yin198716: ½ð±Ò+5, ·ÒëEPI+1, ¡ïÓаïÖú 2013-02-24 12:27:56
| Ò»¸ö¸ß¶ÈÓÅÏÈÎÊÌâÊÇÒѾÅú×¼µÄ¿¹Ñª¹ÜÉú³ÉÖÎÁÆ·½°¸ÊÇ·ñÔÚ¼ÁÁ¿¡¢ÁÆÆÚ¼°ÁªºÏÖÎÁƵȷ½Ã汻ǡµ±²ÉÓ᣼øÓÚȱ·¦¿ÉÓõÄÁÙ´²Êý¾ÝºÍºÏÊʵ͝ÎïÄ£ÐÍ£¬VEGF£¨ÊÜÌ壩ÒÖÖÆ¼ÁÔÚÎ¢×ªÒÆ¼²²¡ÖÐÓÃ×÷¸¨ÖúÒ©£¨ÀýÈ磬Է¢Ö×ÁöÇгý£©Ê±£¬Æä×÷ÓÃÐèÒª½øÒ»²½Ñо¿£¬ |

2Â¥2013-01-31 15:37:08














»Ø¸´´ËÂ¥